A Phase 3 interventional study of E/C/F/TAF in HIV and HBV, sponsored by Gilead Sciences. Completed at 24 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-16.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Coinfection with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Coinfection · United States.
Among the 16 studies in Coinfection with a site in United States, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2014, is one of 2 in phase 3, and was the 9th registered.
92 studies on the registry are indexed under Coinfection; 12 are open to participants now.
Browse Coinfection studies →2 of the 16 studies in Coinfection with a site in United States are open now. Recruiting first, the newest first:
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
Michigan State University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Coinfection studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 79 is close to the median of 75 across 50 interventional studies indexed under Coinfection.
Median enrollment 82 across the 10 interventional studies, 332 across the 6 observational. Of the 13 that completed or were terminated, 6 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 16 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 3 studies filed under Coinfection — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Coinfection with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy, safety, and tolerability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in human immunodeficiency virus (HIV)/hepatitis B virus (HBV) coinfected adults.
Participants will be enrolled into two cohorts:
Key Inclusion Criteria:
Both Cohorts 1 and 2:
No evidence of hepatocellular carcinoma (HCC) or clinical or imaging evidence of cirrhosis (ascites, variceal bleeding, encephalopathy).
--- Subjects should have documentation of an abdominal ultrasound in the 12 months prior to screening, or an abdominal ultrasound at screening, demonstrating the absence of cirrhosis and HCC.
Chronic HBV infection as defined by
At screening: positive total hepatitis B core antibody (HBcAb) and negative immunoglobulin M antibody to hepatitis B core antigen (HBcIgM) antibody, and
Cohort 1 (HIV and HBV treatment naive) only:
Cohort 2 (HIV suppressed) only:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV/HBV coinfected participants who are HIV treatment-naive and HBV treatment-naive will receive E/C/F/TAF for 48 weeks.
Drug: E/C/F/TAF
HIV/HBV coinfected participants who are HIV-suppressed will receive E/C/F/TAF for 48 weeks.
Drug: E/C/F/TAF
Drug pages: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide
E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
Also known as: Genvoya®
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 24
Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL
The percentage of participants with HBV DNA \< 29 IU/mL at Week 24 was calculated using the missing = failure method.
Time frame: Week 24
Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
Time frame: Week 48
Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL
The percentage of participants with HBV DNA \< 29 IU/mL at Week 48 was calculated using the missing = failure method.
Time frame: Week 48
Percentage of Participants With Normalized Alanine Aminotransferase (ALT) at Week 24
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Baseline; Week 24
Percentage of Participants With Normalized ALT at Week 48
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
Time frame: Baseline; Week 48
Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs) at Week 24
Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.
Time frame: Baseline; Week 24
Percentage of Participants With Seroconversion to Anti-HBs at Week 48
Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.
Time frame: Baseline; Week 48
Percentage of Participants With Seroconversion to Hepatitis B e Antibody (Anti-HBe) at Week 24
Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.
Time frame: Baseline; Week 24
Percentage of Participants With Seroconversion to Anti-HBe at Week 48
Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.
Time frame: Baseline; Week 48
Change From Baseline in FibroTest® Score at Week 24
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.
Time frame: Baseline; Week 24
Change From Baseline in FibroTest® Score at Week 48
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.
Time frame: Baseline; Week 48
Participants were enrolled at study sites in North America and Japan. The first participant was screened on 25 February 2014. The last study visit occurred on 26 October 2016.
| Milestone | HIV/HBV Treatment-Naive (Cohort 1) | HIV-Suppressed (Cohort 2) |
|---|---|---|
| Started | 4 | 75 |
| Completed | 2 | 68 |
| Not completed | 2 | 7 |
| Withdrew: Enrolled and never treated | 1 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrew consent | 0 | 4 |
| Withdrew: Lost to follow-up | 1 | 1 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL | 100.0 | 94.4 |
The percentage of participants with HBV DNA \< 29 IU/mL at Week 24 was calculated using the missing = failure method.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL | 33.3 | 86.1 |
The percentage of participants achieving HIV-1 RNA \< 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Plasma HIV-1 RNA Level < 50 Copies/mL | 66.7 | 91.7 |
The percentage of participants with HBV DNA \< 29 IU/mL at Week 48 was calculated using the missing = failure method.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Plasma HBV DNA Levels < 29 IU/mL | 66.7 | 91.7 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Normalized Alanine Aminotransferase (ALT) at Week 24 | 100.0 | 50.0 |
ALT normalization was defined as an ALT value that changed from above the normal range at baseline to within the normal range at the given postbaseline visit.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Normalized ALT at Week 48 | 66.7 | 40.0 |
Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Seroconversion to Hepatitis B Surface Antibody (Anti-HBs) at Week 24 | 0 | 1.4 |
Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Seroconversion to Anti-HBs at Week 48 | 0 | 1.4 |
Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Seroconversion to Hepatitis B e Antibody (Anti-HBe) at Week 24 | 33.3 | 3.3 |
Seroconversion to antibody is defined as (1) antigen loss and (2) positive postbaseline antibody value. Missing = excluded method.
| percentage of participants | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Percentage of Participants With Seroconversion to Anti-HBe at Week 48 | 33.3 | 0 |
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.
| units on a scale | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Change From Baseline in FibroTest® Score at Week 24 | -0.19 (-0.24 to -0.10) | -0.02 (-0.12 to 0.04) |
The FibroTest® score is used to assess liver fibrosis. Scores range from 0.00 to 1.00, with higher scores indicating a greater degree of fibrosis.
| units on a scale | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Change From Baseline in FibroTest® Score at Week 48 | -0.15 (-0.21 to -0.08) | -0.07 (-0.12 to 0.02) |
Collected over Up to 126 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HIV/HBV Treatment-Naive | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| HIV-Suppressed | 0/74 (0%) | 12/74 (16.2%) | 51/74 (68.9%) |
| Event | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/3 | 1/74 |
| GastritisGastrointestinal disorders | 0/3 | 1/74 |
| Small intestinal obstructionGastrointestinal disorders | 0/3 | 1/74 |
| Chest painGeneral disorders | 0/3 | 1/74 |
| Abscess limbInfections and infestations | 0/3 | 1/74 |
| AppendicitisInfections and infestations | 0/3 | 1/74 |
| Meningitis pneumococcalInfections and infestations | 0/3 | 1/74 |
| Pneumococcal bacteraemiaInfections and infestations | 0/3 | 1/74 |
| PneumoniaInfections and infestations | 0/3 | 1/74 |
| Pneumonia pneumococcalInfections and infestations | 0/3 | 1/74 |
| Event | HIV/HBV Treatment-Naive | HIV-Suppressed |
|---|---|---|
| Dental cariesGastrointestinal disorders | 1/3 | 0/74 |
| DiarrhoeaGastrointestinal disorders | 1/3 | 8/74 |
| VomitingGastrointestinal disorders | 1/3 | 2/74 |
| Herpes zosterInfections and infestations | 1/3 | 1/74 |
| NasopharyngitisInfections and infestations | 1/3 | 9/74 |
| SyphilisInfections and infestations | 1/3 | 3/74 |
| Upper respiratory tract infectionInfections and infestations | 1/3 | 17/74 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/3 | 7/74 |
| BronchitisInfections and infestations | 0/3 | 6/74 |
| Back painMusculoskeletal and connective tissue disorders | 0/3 | 6/74 |
Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug.
| Age, Continuous(years) | HIV/HBV Treatment-Naive | HIV-Suppressed | Total |
|---|---|---|---|
| Mean | 27 ± 4.0 | 49 ± 7.8 | 49 ± 8.9 |
| Sex: Female, Male(Participants) | HIV/HBV Treatment-Naive | HIV-Suppressed | Total |
|---|---|---|---|
| Female | 0 | 6 | 6 |
| Male | 3 | 68 | 71 |
| Race/Ethnicity, Customized(participants) | HIV/HBV Treatment-Naive | HIV-Suppressed | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 2 | 7 | 9 |
| Black | 0 | 14 | 14 |
| White | 1 | 50 | 51 |
| Other | 0 | 2 | 2 |
| Race/Ethnicity, Customized(participants) | HIV/HBV Treatment-Naive | HIV-Suppressed | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 12 | 12 |
| Not Hispanic or Latino | 3 | 62 | 65 |
| Region of Enrollment(participants) | HIV/HBV Treatment-Naive | HIV-Suppressed | Total |
|---|---|---|---|
| Canada | 0 | 10 | 10 |
| United States | 1 | 62 | 63 |
| Japan | 2 | 2 | 4 |
| HIV-1 RNA(log10 copies/mL) | HIV/HBV Treatment-Naive | HIV-Suppressed | Total |
|---|---|---|---|
| Mean | 4.20 ± 1.242 | 1.29 ± 0.068 | 1.41 ± 0.606 |
| HIV-1 RNA Category(participants) | HIV/HBV Treatment-Naive | HIV-Suppressed | Total |
|---|---|---|---|
| < 50 copies/mL | 0 | 73 | 73 |
| ≥ 50 copies/mL | 3 | 1 | 4 |
| HBV DNA(log10 IU/mL) | HIV/HBV Treatment-Naive | HIV-Suppressed | Total |
|---|---|---|---|
| Mean | 8.31 ± 0.416 | 1.49 ± 0.883 | 1.75 ± 1.588 |
5 further baseline measures are reported on the registry.
Plan to share: Yes — Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.
Supporting information: Study protocol, Statistical analysis plan
Time frame: 18 months after study completion
Access criteria: A secured external environment with username, password, and RSA code.
Data sharing details ↗ · www.gilead.com
No publications or documents are linked to this record.
Ran from Feb 2014 to primary completion in Jan 2015, 10 months.
Results were first posted in Apr 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Elvitegravir · Cobicistat · Emtricitabine · Tenofovir alafenamide